Home › Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA (pembrolizumab) Combination Trial
 

Keywords :   


Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA (pembrolizumab) Combination Trial

2015-12-10 12:30:08| Merck.com - Product News

Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lillys cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Mercks KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. Language: English read more

Tags: trial combination expand adding

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09When to recline and how to share armrests: Rules for avoiding a mid-flight row
29.09Atlantic Tropical Weather Outlook
29.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 12
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 12
28.09Hurricane Isaac Forecast Advisory Number 12
More »